Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2008 | 1 |
2009 | 2 |
2012 | 3 |
2013 | 1 |
2023 | 0 |
Search Results
6
results
Results by year
Page 1
Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
Bioorg Med Chem. 2012 Nov 15;20(22):6598-612. doi: 10.1016/j.bmc.2012.09.037. Epub 2012 Sep 24.
Bioorg Med Chem. 2012.
PMID: 23062824
KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models.
Shibazaki T, Tomae M, Ishikawa-Takemura Y, Fushimi N, Itoh F, Yamada M, Isaji M.
Shibazaki T, et al. Among authors: ishikawa takemura y.
J Pharmacol Exp Ther. 2012 Aug;342(2):288-96. doi: 10.1124/jpet.112.193045. Epub 2012 Apr 26.
J Pharmacol Exp Ther. 2012.
PMID: 22537769
Item in Clipboard
Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.
Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M.
Katsuno K, et al. Among authors: ishikawa takemura y.
Eur J Pharmacol. 2009 Sep 15;618(1-3):98-104. doi: 10.1016/j.ejphar.2009.07.001. Epub 2009 Jul 15.
Eur J Pharmacol. 2009.
PMID: 19615995
Item in Clipboard
Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1).
Fushimi N, Teranishi H, Shimizu K, Yonekubo S, Ohno K, Miyagi T, Itoh F, Shibazaki T, Tomae M, Ishikawa-Takemura Y, Nakabayashi T, Kamada N, Yamauchi Y, Kobayashi S, Isaji M.
Fushimi N, et al. Among authors: ishikawa takemura y.
Bioorg Med Chem. 2013 Feb 1;21(3):748-65. doi: 10.1016/j.bmc.2012.11.041. Epub 2012 Dec 5.
Bioorg Med Chem. 2013.
PMID: 23273606
Item in Clipboard
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, Kusama H, Isaji M.
Fujimori Y, et al. Among authors: ishikawa takemura y.
Eur J Pharmacol. 2009 May 1;609(1-3):148-54. doi: 10.1016/j.ejphar.2009.03.007. Epub 2009 Mar 10.
Eur J Pharmacol. 2009.
PMID: 19281809
Item in Clipboard
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M.
Fujimori Y, et al. Among authors: ishikawa takemura y.
J Pharmacol Exp Ther. 2008 Oct;327(1):268-76. doi: 10.1124/jpet.108.140210. Epub 2008 Jun 26.
J Pharmacol Exp Ther. 2008.
PMID: 18583547
Item in Clipboard
Cite
Cite